Canine tumours show varied CB1 and CB2 expression; treatment effects remain…

Differential expression of CB1 and CB2 receptors in canine malignant neoplasms.

Journal of comparative pathology • • Highly Relevant
🤖

AI Summary

This study asked whether CB1 and CB2 gene expression differs among canine malignant tumours. Researchers used real-time quantitative PCR to analyse preserved tumour samples from dogs with squamous cell carcinoma, bladder urothelial carcinoma, mammary carcinoma, melanoma, haemangiosarcoma or osteosarcoma, comparing expression with normal canine brain for CB1 and lymph node for CB2.

CB1 expression was significantly lower than its control in all tumour types except melanoma. CB2 expression was significantly lower in squamous cell carcinoma, bladder urothelial carcinoma, osteosarcoma and mammary carcinoma, but not in melanoma or haemangiosarcoma; expression also differed among tumour types for both receptors. These findings suggest tumour-specific differences in components of the endocannabinoid system, but this gene-expression study cannot establish what the differences mean for tumour behaviour or whether cannabinoid-based treatments would help. This is an abstract-based summary, not a review of the full text.

💡 Key Findings

1
CB1 gene expression was significantly reduced in five tumour types, but not in melanoma.
High
95%
2
CB2 gene expression was significantly reduced in squamous cell carcinoma, bladder urothelial carcinoma, osteosarcoma and mammary carcinoma, but not in melanoma or haemangiosarcoma.
High
95%
3
Expression of both receptors differed significantly among tumour types, indicating tumour-dependent patterns.
High
95%
4
The study measured receptor gene expression in canine tumour samples; it does not establish effects on cancer progression or response to cannabinoid treatment.
High
99%

📄 Original Abstract

The endocannabinoid system (ECS), composed of cannabinoid receptors CB1 and CB2, plays a role in tumour biology through modulation of proliferation, apoptosis and immune response. However, its involvement in canine neoplasms remains poorly understood. This study evaluated CB1 and CB2 gene expression in different canine malignant tumours. Formalin-fixed, paraffin wax-embedded samples from squamous cell carcinoma (SCC), urothelial carcinoma of the bladder (UC), mammary carcinoma, melanoma, haemangiosarcoma and osteosarcoma were analysed by real-time quantitative polymerase chain reaction, and relative expression was calculated using normal canine brain as control for CB1 and lymph node for CB2. CB1 gene expression was significantly reduced in SCC (P = 0.0070), UC (P = 0.0018), haemangiosarcoma (P = 0.0021), osteosarcoma (OSA) (P = 0.0121) and mammary carcinoma (P = 0.0121), but not in melanoma (P = 0.6286). In contrast, CB2 gene expression was significantly reduced in SCC (P = 0.0020), UC (P = 0.0011), OSA (p P = 0.0040) and mammary carcinoma (P = 0.0286), but not in melanoma (P = 0.1746) or haemangiosarcoma (P = 0.4346). Analysis revealed significant differences among tumour types for both CB1 (P = 0.0010) and CB2 (P = 0.0010) expression. These findings demonstrate that cannabinoid receptors, key components of the ECS, are expressed at different levels in canine tumours, with the CB1 gene predominantly downregulated and more variable tumour-specific expression patterns for the CB2 gene. Overall, CB1 downregulation was a recurrent finding across canine malignant neoplasms, whereas CB2 expression showed a more tumour-dependent pattern, indicating differential involvement of cannabinoid receptors across tumour types.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.